GlassScriptPhysician profile
Nancy Banh
NPI 1851925853
$5,708.50
in general payments reported to CMS, 2019-2025
22 companies · $894 in 2025
The $894 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,263 · 2022: $1,606 · 2023: $1,080 · 2024: $866 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,839.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,203.31 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $918.75 | 2021-2024 | Brilinta, Wainua, Farxiga |
| Novo Nordisk INC | $775.13 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $408.33 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $352.27 | 2021-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $329.80 | 2022-2025 | |
| Amarin Pharma, INC. | $322.56 | 2021-2022 | |
| Amgen INC. | $240.44 | 2022-2025 | Repatha |
| Bridgebio Pharma, INC. | $214.96 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $188.35 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $164.38 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $100.76 | 2021-2024 | Nexletol |
| Lilly USA, LLC | $84.55 | 2021-2022 | |
| Pfizer INC. | $65.64 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $65.31 | 2023-2024 | Inpefa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $64.36 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Novartis Pharmaceuticals Corporation | $52.95 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $49.03 | 2024-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $47.60 | 2025 | Evkeeza |
| Inspire Medical Systems, INC. | $22.55 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $22.36 | 2021 | |
| Scpharmaceuticals INC. | $15.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Banh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.